Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (21387)	3/16/1999 5:05:00 PM
From: Lucky888	Read Replies (1) \| Respond to of 122087

A@P, This is good, I am still shorting ENMD; However I selected to long EFAX after your warning that it COULD go to 50s :) Only a few hundred shares for fun. :) L.

To: Anthony@Pacific who wrote (21387)	3/16/1999 5:07:00 PM
From: CatLady	Respond to of 122087

Hey Auric! Was that you selling EFAX around 3:45? I couldn't borrow IFLY or FAXX today, so I settled for taking another shot at EFAX. So far so good. :-)

To: Anthony@Pacific who wrote (21387)	3/16/1999 5:09:00 PM
From: Bear Down	Respond to of 122087

HELO........ late blurp on CNBC about some reco....nothin more that I can find. for the price run

To: Anthony@Pacific who wrote (21387)	3/16/1999 5:17:00 PM
From: M. LaMancha	Read Replies (1) \| Respond to of 122087

ENMD -- thought you'd be interested in following excerpt from article that sparked the sell off: "It's our belief that drug companies can produce much smaller molecules than angiostatin to block the enzyme's activity," Dr. Pizzo says. Duke has filed for a patent for the binding site it uncovered and has been contacted by several drug makers interested in developing their own drugs, he says. Funds from Glaxo Wellcome PLC helped support the research, and the British drug giant has the first right to develop a drug if it chooses. Meanwhile, EntreMed officials say they are going ahead with plans to test angiostatin in patients, perhaps as early as next year. TOO BAD GLX IS SO HUGE THAT HAVING RIGHTS TO THIS PRODUCT PROBABLY WON'T IMPACT ITS PRICE.